Logo image of VBIV

VBI VACCINES INC (VBIV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VBIV - CA91822J2020 - Common Stock

0.0653 USD
-0.07 (-50.87%)
Last: 8/7/2024, 8:00:02 PM
0.045 USD
-0.02 (-31.09%)
After Hours: 8/7/2024, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VBIV. VBIV was compared to 525 industry peers in the Biotechnology industry. VBIV has a bad profitability rating. Also its financial health evaluation is rather negative. VBIV shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VBIV had negative earnings in the past year.
  • VBIV had a negative operating cash flow in the past year.
  • In the past 5 years VBIV always reported negative net income.
  • VBIV had a negative operating cash flow in each of the past 5 years.
VBIV Yearly Net Income VS EBIT VS OCF VS FCFVBIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • VBIV's Return On Assets of -111.34% is on the low side compared to the rest of the industry. VBIV is outperformed by 80.07% of its industry peers.
Industry RankSector Rank
ROA -111.34%
ROE N/A
ROIC N/A
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
VBIV Yearly ROA, ROE, ROICVBIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

  • VBIV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VBIV Yearly Profit, Operating, Gross MarginsVBIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

  • VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VBIV has more shares outstanding
  • VBIV has a worse debt/assets ratio than last year.
VBIV Yearly Shares OutstandingVBIV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
VBIV Yearly Total Debt VS Total AssetsVBIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -13.90, we must say that VBIV is in the distress zone and has some risk of bankruptcy.
  • VBIV's Altman-Z score of -13.90 is on the low side compared to the rest of the industry. VBIV is outperformed by 83.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.9
ROIC/WACCN/A
WACC9.93%
VBIV Yearly LT Debt VS Equity VS FCFVBIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 0.34 indicates that VBIV may have some problems paying its short term obligations.
  • VBIV's Current ratio of 0.34 is on the low side compared to the rest of the industry. VBIV is outperformed by 95.80% of its industry peers.
  • A Quick Ratio of 0.21 indicates that VBIV may have some problems paying its short term obligations.
  • VBIV's Quick ratio of 0.21 is on the low side compared to the rest of the industry. VBIV is outperformed by 97.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.21
VBIV Yearly Current Assets VS Current LiabilitesVBIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

  • The earnings per share for VBIV have decreased strongly by -90.48% in the last year.
  • The Revenue has grown by 548.76% in the past year. This is a very strong growth!
  • VBIV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.91% yearly.
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%

3.2 Future

  • Based on estimates for the next years, VBIV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.46% on average per year.
  • The Revenue is expected to grow by 64.62% on average over the next years. This is a very strong growth
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VBIV Yearly Revenue VS EstimatesVBIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
VBIV Yearly EPS VS EstimatesVBIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VBIV. In the last year negative earnings were reported.
  • Also next year VBIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VBIV Price Earnings VS Forward Price EarningsVBIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VBIV Per share dataVBIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • VBIV's earnings are expected to grow with 25.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.33%
EPS Next 3Y25.46%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for VBIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VBI VACCINES INC

NASDAQ:VBIV (8/7/2024, 8:00:02 PM)

After market: 0.045 -0.02 (-31.09%)

0.0653

-0.07 (-50.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07
Earnings (Next)11-12
Inst Owners0.03%
Inst Owner Change-99.13%
Ins Owners66.54%
Ins Owner Change0%
Market Cap1.87M
Revenue(TTM)9.41M
Net Income(TTM)-84.00M
Analysts82.86
Price Target5.1 (7710.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.25%
Min EPS beat(2)-35.04%
Max EPS beat(2)95.54%
EPS beat(4)1
Avg EPS beat(4)-169%
Min EPS beat(4)-607.28%
Max EPS beat(4)95.54%
EPS beat(8)1
Avg EPS beat(8)-125.37%
EPS beat(12)4
Avg EPS beat(12)-83.31%
EPS beat(16)5
Avg EPS beat(16)-65.27%
Revenue beat(2)0
Avg Revenue beat(2)-71.33%
Min Revenue beat(2)-84.4%
Max Revenue beat(2)-58.27%
Revenue beat(4)0
Avg Revenue beat(4)-54.42%
Min Revenue beat(4)-84.4%
Max Revenue beat(4)-24.02%
Revenue beat(8)0
Avg Revenue beat(8)-59.02%
Revenue beat(12)1
Avg Revenue beat(12)-48.87%
Revenue beat(16)1
Avg Revenue beat(16)-48.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.8
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.33
BVpS-0.19
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.73%
Cap/Sales 5.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.21
Altman-Z -13.9
F-Score4
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)120.98%
Cap/Depr(5y)145.88%
Cap/Sales(3y)243.1%
Cap/Sales(5y)197.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A
EBIT growth 1Y44.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.15%
OCF growth 3YN/A
OCF growth 5YN/A

VBI VACCINES INC / VBIV FAQ

Can you provide the ChartMill fundamental rating for VBI VACCINES INC?

ChartMill assigns a fundamental rating of 2 / 10 to VBIV.


Can you provide the valuation status for VBI VACCINES INC?

ChartMill assigns a valuation rating of 1 / 10 to VBI VACCINES INC (VBIV). This can be considered as Overvalued.


How profitable is VBI VACCINES INC (VBIV) stock?

VBI VACCINES INC (VBIV) has a profitability rating of 0 / 10.


What is the expected EPS growth for VBI VACCINES INC (VBIV) stock?

The Earnings per Share (EPS) of VBI VACCINES INC (VBIV) is expected to grow by 86.5% in the next year.